Avadel's $20M upfront for sleep drug; Congruence gets $32M for obesity drug

Plus, news about Congruence Therapeutics, Artelo Biosciences, Ashvattha Therapeutics, Biocytogen and AL-S Pharma: 💤 Avadel licenses sleep drug for $20M upfront: Avadel will develop and sell XWPharma’s valiloxybate, a GABA-B agonist ...